IMPLANET: Nomination of an International Expert in Healthcare Strategy Advising to the Board of Directors
PARIS--(BUSINESS WIRE)--Regulatory News:
IMPLANET (Paris:IMPL) (Euronext: IMPL, FR0010458729, PEA-PME eligible), a medical technology company specializing in vertebral and knee-surgery implants, announces today the decision of the Board of Directors to nominate Mrs. Paula Ness Speers as a new advisor.
Based in the US, and drawing on nearly 30 years of experience in strategy development for global companies, Paula Ness Speers brings a wealth of specific expertise in the healthcare sector. During her 7 years at Bain & Company (Boston, MA), Paula led strategy consulting projects for numerous Fortune 100 companies involved in a variety of technology-based product development and sales. While at Bain she also created and led the R&D Practice Area, focused on helping younger and more innovative companies develop creative commercial strategies, as well as successfully address a variety of manufacturing, operational and cost challenges they faced in their early stages.
Since 1992, Paula has co-founded and led Health Advances, a 100-person strategy consulting firm with offices in Boston, San Francisco, Washington DC, and Zurich focusing completely on the healthcare sector. The firm’s clients range from entrepreneurial start-ups to the largest public and global companies in the healthcare sector. During these past nearly 23 years, Paula has consulted to a broad range of healthcare product and service companies, as well as financial investors in the sector. She has developed particular expertise in the orthopedics and spine sector, working with a range of clients from OEMs to materials and component manufacturers servicing the orthopedic and spine sector. She also leads many of the firm’s cost-effectiveness studies and market access strategies for these and other clients in the healthcare sector.
Paula Ness Speers says, “I am very excited to join the Board of Directors of IMPLANET. I enthusiastically share Management’s and the Board’s vision to establish JAZZ as a worldwide brand in spinal surgery addressing some of the most complex spine cases around the globe. The high quality team assembled on the Board and in the Management team distinguishes IMPLANET in its capacity to rapidly expand its strong EU-based successes into the US spine market and beyond. I am looking forward to assisting IMPLANET in achieving its growth and clinical distinction by participating in the establishment of major strategic initiatives in the US and globally in the future.”
Ludovic Lastennet, CEO, concludes, “We are proud to welcome Paula Ness Speers as an independent advisor. Her multiple successes in the establishment and execution of complex growth strategies in the healthcare industry, from product concept to launch and commercial optimization, will be a major asset that allows IMPLANET to push forward its international growth plans.”
Next financial press release: revenue for the 1st half of 2014, on 28 July 2014
Founded in 2007 and based near Bordeaux, IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery. Its flagship product, the JAZZ latest-generation implant, aims to improve the treatment of spinal pathologies requiring vertebral fusion surgery. IMPLANET’s proven orthopedic platform, based on perfectly controlling the traceability of its products, gives the Company the proven ability to enhance this innovation. Protected by four families of international patents, JAZZ has obtained 510(k) regulatory approval from the Food and Drug Administration (FDA) in the United States and the CE mark. IMPLANET employs 38 staff and recorded 2013 sales of €6.7 million.
For further information, please visit www.implanet.com